Communiqués Astellas Pharma Inc. OTC Markets

Actions

ALPMY

US04623U1025

Temps Différé OTC Markets Autres places de cotation 18:22:31 20/06/2024			Varia. 5j.	Varia. 1 janv.
9,39 ^USD	-1,05 %		-2,09 %	-21,09 %

21/05	Astellas annonce une collaboration avec YASKAWA pour créer un écosystème de thérapie cellulaire innovant grâce à l'intégration des technologies pharmaceutiques et robotiques	CI
08/05	Astellas inaugure un nouveau centre d'innovation ultramoderne de 90 millions de dollars sur la côte ouest, dans le corridor biotechnologique de South San Francisco	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM	23/04	AQ
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy	04/04	AQ
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer	27/03	AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy	27/03	AQ
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting	25/03	AQ
Xyphos Biosciences enters research collaboration and license agreement with Kelonia Therapeutics	16/02	AQ
Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer	31/01	AQ
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager	28/12	BU
Pfizer Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC plus PD-1 to Treat Advanced Bladder Cancer	18/12	AQ
Astellas Pharma Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer	18/12	AQ
Astellas Pharma Inc. - EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children	18/12	AQ
Astellas secures EC approval for VMS treatment, fezolinetant	14/12	AQ
Astellas VEOZA Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause	11/12	AQ
Outgoing Japan envoy regrets not being able to rescue detained man	04/12	AQ
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies	01/12	AQ
Astellas Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy	30/11	AQ
Japan envoy meets citizen detained in China over spying for 1st time	28/11	AQ
Astellas Pharma Inc. - University of Tsukuba and Astellas Confirm a Strategic Partnership	17/11	AQ
Pfizer and Astellas XTANDI Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting	17/11	AQ
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors	25/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Astellas Pharma Inc. OTC Markets

Actions

ALPMY

US04623U1025

Communiqués

Filtres